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MicroRNAs (miRNAs) have recently emerged as a new class of modulators of gene expression. miRNAs control protein synthesis
by targeting mRNAs for translational repression or degradation at the posttranscriptional level. These noncoding RNAs are
endogenous, single-stranded molecules approximately 22 nucleotides in length and have roles in multiple facets of immunity,
from regulation of development of key cellular players to activation and function in immune responses. Recent studies have shown
that dysregulation of miRNAs involved in immune responses leads to autoimmunity. Multiple sclerosis (MS) serves as an example
of a chronic and organ-speciﬁc autoimmune disease in which miRNAs modulate immune responses in the peripheral immune
compartment and the neuroinﬂammatory process in the brain. For MS, miRNAs have the potential to serve as modifying drugs.
In this review, we summarize current knowledge of miRNA biogenesis and mode of action and the diverse roles of miRNAs in
modulating the immune and inﬂammatory responses. We also review the role of miRNAs in autoimmunity, focusing on emerging
data regarding miRNA expression patterns in MS. Finally, we discuss the potential of miRNAs as a disease marker and a novel
therapeutic target in MS. Better understanding of the role of miRNAs in MS will improve our knowledge of the pathogenesis of
this disease.
1.Introduction
MicroRNAs (miRNAs) represent a class of noncoding RNA
molecules that play pivotal roles in cellular and devel-
opmental processes by regulating gene expression at the
posttranscriptional level. miRNAs are endogenous, evolu-
tionarily conserved, single-stranded RNAs approximately
22 nucleotides in length that suppress the expression of
protein-coding genes by directing translational repression
through base-pairing with complementary messenger RNA
(mRNA)and/or by promoting degradation of target mRNA
degradation [1,2].Sincetheidentiﬁcation ofthemiRNAlin-
4 as a regulator of developmental timing in the nematode
Caenorhabditis elegans (C. elegans) in 1993 [3, 4], more
than 17000 miRNAs have been recognized in 142 species.
Currently, 1048 human miRNAs are registered in the
miRNA registry (miRBase) which is the most commonly
used database for miRNA (September 2010, release 16,
http://www.mirbase.org/)[ 5]. miRBase reports 672 miRNAs
in mouse and 408 miRNAs in rat, with new miRNAs
constantly being identiﬁed, though the biologic function of
only a fraction of miRNAs has been elucidated. miRNAs are
predicted to regulate up to one-third of all human protein-
coding genes. Unraveling the miRNA translational silencing
network remains a challenge in part because individual
miRNAs typically target several transcripts rather just one
speciﬁc gene and a single mRNA can be regulated by
several distinct miRNAs that act cooperatively [2]. Ribo-
some proﬁling experiments showed that miRNAs mediate
destabilization of target mRNAs resulting in reduced protein
levels [6]. miRNAs play an important role in diverse biologic
processes such as development, cell proliferation and diﬀer-
entiation, apoptosis, oncogenesis, metabolism, angiogenesis,
and inﬂammation. The expression of miRNAs is initially
controlledattheleveloftranscriptionbytranscriptionfactors
that regulate the production of miRNA-containing primary
t r a n s c r i p t si ns p e c i ﬁ cc e l lt y p e sd u r i n gd e v e l o p m e n to ri n
responsetodiﬀerentenvironmentalsignals.Dysregulationof
miRNA expression and function is associated with a variety2 Autoimmune Diseases
of human diseases including cancer, neurodegeneration and
autoimmunity [7, 8].
The regulation of mammalian immune responses by
miRNAsisaconceptcurrentlyevidencedbyrapidlyaccumu-
lating data [9, 10]. miRNAs have unique expression proﬁles
in cells of the innate and adaptive immune systems and
have pivotal roles in the regulation of both cell development
and function. Recent studies focused on the networkwide
role of miRNA or the functions of individual miRNAs have
revealed that these small noncoding RNAs are involved in T
and B cell diﬀerentiation in the thymus and bone marrow,
respectively. During the eﬀector phases of adaptive immu-
nity, miRNAs contribute to the diﬀerentiation of T cells
into functional lineages, class switching and germinal centre
formation in B cells and activation of antigen-presenting
cells (APCs) through pattern recognition pathways [11].
miRNAs are also directly involved in innate immunity and
transduction signalling by Toll-like receptors (TLRs) and
the ensuing cytokine response [12]. Up to one half of
innate immune genes are predicted to be under the direct
regulation of miRNAs. With the capacity of miRNAs to
regulate the survival and death of T and B cells, control over
miRNA expression is essential to prevent adaptive immune
cells from unregulated proliferation leading to cancer or
autoimmunity [13, 14]. miRNAs are diﬀerentially expressed
in autoimmune diseases and miRNA regulation may have an
impact on the development or prevention of autoimmunity.
miRNA dysregulation is linked to autoimmune diseases
such as rheumatoid arthritis, systemic lupus erythematosus,
Sj¨ ogren’s syndrome, psoriasis, and MS [15–17]. MS is the
most common autoimmune disease of the central nervous
system (CNS). It is a chronic, neuroinﬂammatory, and
demyelinating disease in which myelin speciﬁc autoreactive
CD4+ T cells become activated in the peripheral immune
compartment, cross the blood-brain barrier (BBB), and
promote neurological disability [18, 19]. Both genetic (HLA
type) and environmental causes for MS have been suggested.
Recently, genomewide association studies have identiﬁed
additional potential MS susceptibility loci [20, 21]. Recent
studies suggest that miRNA dysregulation may contribute
to the pathogenesis of MS. Thus, better understanding of
miRNA mechanisms might shed light, not only on the
pathogenesis of MS but also on potential approaches for
managing or even suppressing the disease. In this review,
we brieﬂy overview the biogenesis and action mechanisms of
miRNAs and summarize recent advances in our understand-
ing of both the intended functions of miRNAs in managing
immune responses. We then review evolving knowledge on
the role of miRNA in autoimmunity and emerging data
regarding miRNA expression patterns in MS. Finally, we
also discuss the potential of miRNAs as a diagnostic and
prognosticindicatorsofdiseasetypeandstatusandasanovel
therapeutic target in MS.
2. MicroRNAs
2.1. MicroRNA Biogenesis. All miRNAs are processed and
maturated through a complex biogenesis process involving
multiple protein catalysts, accessory proteins, and macro-
molecular complexes following a coordinated series of
events. The reader is referred to excellent recent reviews for
detailed discussions of miRNA biogenesis and its regulation
[22–25]. MicroRNAs can be encoded by independent genes
but may also be processed from a variety of diﬀerent RNA
species, including introns, 3 - U T Ro fm R N A s ,l o n gn o n -
coding RNAs, transposable elements, and genomic repeats
[26–32]. miRNAs are expressed as 21–23 nucleotide RNA
molecules initially transcribed by RNA polymerase II as
long primary miRNAs (pri-microRNAs). Although most of
the miRNA genes are transcribed by RNA Polymerase II,
a cluster of human miRNAs have recently been shown to
utilize RNA Polymerase III for their transcription [33]. Pri-
miRNAs are typically 3 to 4 kilobases long single-stranded
RNAs with 5  cap, 3  poly(A) tail and complicated secondary
structure [34–37]. Pri-miRNAs are processed in the nucleus
into one or more precursor-miRNAs (pre-miRNAs) with an
approximately 70-nt loop structure. Processing is performed
by a protein complex named microprocessor complex con-
sisting of the nuclease Drosha (nuclear RNase III) and the
stranded RNA-binding protein, human DiGeorge syndrome
critical region gene 8 (DGCR8) (also known as Pasha in
ﬂies) [35, 37–42]. Drosha functions as the catalytic subunit
while DGCR8 recognizes the RNA substrate. Pre-miRNAs
areexportedfromthenucleustothecytoplasmbyexportin-5
which speciﬁcally recognizes the characteristic end structure
ofpre-miRNAs[43–46].Inthecytoplasm,anotherRNaseIII,
known as Dicer, further processes the pre-miR into mature
m i R N A ,w h i c hi sd o u b l es t r a n d e d( m i R N Ad u p l e x )[ 47, 48].
After Dicer processing, the miRNA duplex is unwound and
a strand (known as miRNA strand or guide strand) binds
to an Argonaute 2 (Ago 2) protein (eIF2C2 in human) in
a process that is referred to as miRNA loading or assembly,
while the complementary strand (known as miRNA∗ strand,
star strand or passenger strand) is degraded. The eﬀector
complex that mediates catalytic mRNA cleavage is known
as RNA-induced silencing complex (RISC), and the eﬀector
complex that mediates translational repression directed by
miRNAs is known as micro-ribonucleoprotein complex
(miRNP) [49–51]. The single stranded mature microRNA
must associate with the RISC. Mature microRNAs are
incorporated into a miRNP (Figure 1). In this complex,
which includes the Dicer-transactivation-responsive RNA-
bindingprotein(TRBP)-PACT-Ago2,microRNAscandirect
downregulation by two mechanisms: translational inhibition
and target mRNA cleavage [52–55]. Perfect match with the
target results in mRNA degradation whereas partial match
leads to translational inhibition.
Inﬂammation has been reported to regulate miRNA
biogenesis; TLR ligands, antigens, or cytokines can modulate
miRNA expression level through regulation of speciﬁc
transcription factors [2, 9, 56]. Cytokines have been shown
to regulate Dicer expression resulting in alteration of pre-
miRNA processing. Interferon-beta (IFN-β) has been shown
to inhibit Dicer expression, which results in decrease of
pre-miRNA processing, whereas IFN-γ induces pre-miRNA
processing [57].Autoimmune Diseases 3
2.2.DetectionofMicroRNAs. InformationaboutmiRNAand
target expression patterns can help to assess the likelihood
that a predicted miRNA-target relationship is relevant in
vivo [58]. Expression of a miRNA can be measured by
molecular biology techniques, such as Northern blotting,
RNase protection assay, polymerase chain reaction- (PCR-)
based techniques, and high throughput assays [59–61].
miRNA expression proﬁles were ﬁrst generated by small
RNA cloning and Northern blotting [4, 62–67]. The small
size of miRNAs initially hampered PCR-based methods [61].
However, since the development of quantitative real-time
PCR, PCR-based techniques have become very popular due
to their high sensitivity [62, 68, 69]. In situ hybridization
has provided further insight into the tissue-speciﬁc expres-
sion of pri- and mature miRNAs [62, 70–74]. Microarray
techniques are widely used to comprehensively assay the
entire miRNome (the global miRNA expression proﬁle) in
t i s s u e so ri nc e l ll i n e s[ 62, 68, 75–83]. In addition, serial
analyses of gene expression (SAGE) adapted for small RNAs
have been used to obtain miRNomes [84]. Interest in the
SAGE approach was stimulated by recent innovations in
next generation (deep) sequencing methods that provide a
powerful tool for various genomics studies [85–87]. Overall,
these technical improvements are expected to greatly widen
the repertoire of known miRNAs in a variety of biological
systems [61]. Emerging techniques for miRNA detection and
quantiﬁcation, including luminescence-based, ﬂuorescence-
based,electrochemical,colorimetric,andenzyme-based,and
nanotechnology-based methods have recently been reviewed
[88]. Whereas expression analyses are required to identify
miRNAs with altered expression patterns in diseased tissues,
functional analyses of the ability of these miRNAs to regulate
expression of target mRNAs are essential to understand their
impact on pathogenic pathways and processes.
3.MicroRNAs and Immunity
Clearly, both innate and adaptive immune responses are
extremely highly regulated. Recent work from a number of
laboratories has revealed that miRNAs play an important
role in this intricate system (Table 1). miRNAs have unique
expression patterns in immune cells and play a pivotal role in
their development, maturation, and function.
3.1. Role of MicroRNAs in Immune Cell Development. miR-
NAs have an important role in regulating stem cell self-
renewal and diﬀerentiation by repressing the translation
of selected mRNAs in stem cells and diﬀerentiating into
daughter cells. Such a role has been shown in embryonic
stem cells, germline stem cells and various somatic tissue
stem cells [89]. The ﬁrst studies implicating miRNAs in
immunological processes were originated from expression
proﬁling of haematopoietic cells during their development.
Haematopoietic stem cells reside mainly in the bone marrow
and give rise to all blood cell lineages, including cells that
constitute the immune system [9]. These cells must maintain
a precise balance between self-renewal and diﬀerentiation
into multipotent progenitors, which subsequently give rise
to both the common lymphoid and common myeloid
progenitors of the haematopoietic system [9, 90]. Systematic
investigation of miRNA levels in hematopoietic cell lineages
has identiﬁed miRNAs that are now considered as markers of
these lineages [91–93]. Peculiar miRNA proﬁles in diﬀerent
haematopoietic organs and cell types suggest that miRNAs
are dynamically regulated during early haematopoiesis, lin-
eagecommitment,andthedevelopmentofimmunecellsand
are involved in the regulation of these processes.
One of the ﬁrst miRNAs described to have a role in
immune cell development was miR-181a which is highly
expressed in thymus cells and expressed at lower levels in
the heart, lymph nodes, and bone marrow [91, 94]. In
bone marrow-derived B cells, miR-181a expression has been
shown to decrease during B cell development from the
pro-B to the pre-B cell stage [91]. miR-181a inhibits the
transition of pro-B to the pre-B cell stage. Moreover, miR-
181a was identiﬁed as a positive regulator of B lymphocyte
diﬀerentiation based on evidence that expression of miR-
181a in hematopoietic stem and progenitor cells resulted in
an increase in CD19+ B cells and a decrease in CD8+ T cells
[91]. Interestingly, miR-181a is also involved in thymic T cell
diﬀerentiation, by deﬁning the activation threshold of T cell
receptor (TCR) [94]. This miRNA modulates TCR signaling,
thus aﬀecting the sensitivity of T cells to antigens [94].
Other examples of miRNA-mediated regulation of immune
cell development include miR-223 which was identiﬁed as
an essential modulator of granulocytic diﬀerentiation [95]
and miR-150 which has been shown to be critical for
Bc e l ld i ﬀerentiation [96, 97]. Collectively, these studies
demonstrate that miRNAs play critical roles at distinct stages
of immune cell development.
3.2.MicroRNAsinAdaptiveImmuneResponses. Theadaptive
oracquiredimmunesysteminvolvestheselectiverecognition
andremovalofnonselfbytheTCRsonTcellsandantibodies
produced by B cells. The maturation, proliferation, diﬀeren-
tiation, and activation of T and B cells are complex processes
tightly controlled at diﬀerent levels including miRNA-
mediated posttranscriptional gene regulation [11]. Adaptive
immunity refers to immune responses to antigens that
undergo learning processes and provide speciﬁc memory.
Once APCs capture a pathogen, they display foreign anti-
gens complexed with major histocompatibility complexes
(MHCs) on their surface to enable recognition of the antigen
by na¨ ıve T cells to induce the adaptive immune response
[19]. The combination of this interaction further drives the
upregulation of both CD80 and CD86 on the surface of
APCs. CD80 and CD86 identify two additional receptors,
CD28 and Cytotoxic T-lymphocyte antigen 4 (CTLA4), on
the surface of the T cells to provide a second signal to
APCs [19]. CD28 is associated with activation of the T cell
whereas CTLA4 is more regulatory. After this second signal,
the T cells become activated, and APCs begin to secrete
important cytokines, including IL-12 and IL-23, which bind
to speciﬁc receptors on T cells and drive them to secrete
diﬀerent cytokines, such as IFN-γ or IL-17, depending on
the cytokine milieu. T cells also begin to secrete IL-2, which4 Autoimmune Diseases
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Figure 1:miRNAgenesaretranscribedintheformofPri-miRNA.TheDGCR8-DroshacomplexprocessesintheformPre-miRNAfollowed
by transport into cytoplasm by Exportin-5. In cytoplasm, Pre-miRNA is processed by Dicer into miRNA duplex. Of miRNA duplex, one
strand is loaded into RISC complex, which functions for either mRNA degradation or translational repression.
then activates its own IL-2 receptor [19]. Upon activation
of their TCR in the presence of costimulatory molecules,
na¨ ıve T cells diﬀerentiate into various subsets of eﬀector T
cells with distinct eﬀector functions (e.g., Th1, Th2, Th17,
Th9). This diﬀerentiation is directed by a speciﬁc cytokine
milieu leading to the expression of transcription factors
speciﬁc for the respective lineages. The expression levels
of all molecules involved in adaptive immune responses
(transcription factors, cell surface receptors, cytokines, and
their receptors) may be regulated by miRNAs as discussed
below.
3.2.1. T Cells. The development of T cells in the thymus and
their activation in the periphery are controlled by complex
protein signalling networks that are subject to regulation by
miRNAs [9, 98]. miRNA expression proﬁles vary between
T cell subsets and diﬀerent developmental stages [92, 99].
Speciﬁc deletion of Dicer in the T cell lineage resulted in
impaired T cell development and aberrant T helper cell
diﬀerentiation and cytokine production [100]. A severe
block in peripheral CD8+ T cell development was observed
upon Dicer deletion in the thymus. However, Dicer-deﬁcient
CD4+ T cells, although reduced in numbers, were viable
and could be analyzed further. These cells were defective
in microRNA processing, and upon stimulation, they pro-
liferated poorly and underwent increased apoptosis [100].
Deletion of Dicer at an early stage of T cell development
compromised the survival of alpha-beta lineage cells whereas
the numbers of gamma-delta-expressing thymocytes were
not aﬀected in developing thymocytes [101]. Mice with
higher expression of miR-17–92 in lymphocytes developed
lymphoproliferative disease and autoimmunity and died
prematurely. Lymphocytes from these mice showed more
proliferation and less activation-induced cell death. The
miR-17–92 miRNA suppressed expression of the tumor
suppressor PTEN and the proapoptotic protein Bim [102].
T cell sensitivity to antigen is intrinsically regulated during
maturation to ensure proper development of immunity
and tolerance. Increasing miR-181a expression in mature
T cells augments the sensitivity to peptide antigens while
inhibiting miR-181a expression in the immature T cells
reduces sensitivity and impairs both positive selection and
negative selection [94]. These eﬀects are in part achieved byAutoimmune Diseases 5
the downregulation of multiple phosphatases, which leads to
elevated steady-state levels of phosphorylated intermediates
and a reduction of the TCR signaling threshold. T cell
activation requires signaling through the TCR and costim-
ulatory molecules, such as CD28. Costimulation-dependent
upregulation of miR-214 promotes T cell activation by
targeting the negative regulator Pten. Thus, the requirement
for T cell costimulation is, in part, related to its ability to
regulate expression of miRNAs that control T cell activation
[103].
Recent data have also indicated a role for miRNAs in the
diﬀerentiation of T cells into distinct eﬀector T helper cell
subsets. miR-155 has an important role in the mammalian
immune system, speciﬁcally in regulating T helper cell
diﬀerentiation and the germinal center reaction to produce
an optimal T cell-dependent antibody response [104]. miR-
155 exerts this control, at least in part, by regulating cytokine
production. Many types of specialized Th cells, including
Th1, Th2, Th17, Th9, follicular helper T, and Treg, have
been identiﬁed. Diﬀerent Th cells are committed to their
paths but recent emerging evidence suggests that under
certain conditions, seemingly committed Th cells possess
plasticity and may convert into other types of eﬀector cells
[105]. There is growing evidence that clinically similar forms
of autoimmune demyelinating disease can be driven by
myelin-speciﬁc T cells of distinct lineages with diﬀerent
degrees of dependence on IL-17 production to achieve their
pathological eﬀects [106]. miRNAs play an important role in
the development of Th17 cells [107]. Bcl-6, a transcriptional
repressor, binds to the promoters of the Th1 and Th17
cell transcriptional regulators T-bet and RORgammat and
represses IFN-γ and IL-17 production. Bcl-6 also represses
expression of many miRNAs predicted to control the T fol-
licular cell signature, including miR-17-92, which represses
CXCR5 expression. Thus, Bcl-6 positively directs T follicular
cell diﬀerentiation,throughcombinedrepressionofmiRNAs
and transcription factors [108]. miRNAs are also essential in
the development, diﬀerentiation, and function of Treg cells
which are potent immune regulators [109]. Recent studies
showed a crucial role for miRNAs in Treg cell biology and
the prevention of spontaneous autoimmunity [110–112].
miR-155 deﬁciency in Treg cells results in increased
suppressor of cytokine signaling 1 (SOCS1) expression
accompaniedbyimpairedactivationofsignaltransducerand
activator of transcription 5 (STAT5) transcription factor in
response to limiting amounts of IL-2. Forkhead box P3-
(Foxp3-) dependent regulation of miR155 maintains com-
petitive ﬁtness of Treg cell subsets by targeting SOCS1 [113].
miR-155-deﬁcientmicehavereducednumbersofTregs,both
in the thymus and periphery, due to impaired development.
However, no evidence for defective suppressor activity of
miR-155-deﬁcient Tregs was found, either in vitro or in vivo,
suggesting that miR-155 contributes to Treg development,
but that additional miRNAs control Treg function [114].
The expression of miR-142-3p was recently shown to be
repressed by Foxp3, leading to increased production of cyclic
AMP and suppressor function of Treg cells [115]. Depleting
miRNAs by eliminating Dicer reduces Treg cell numbers
and results in immune pathology [116]. Dicer facilitates, in
a cell-autonomous fashion, the development of Treg cells in
the thymus and the eﬃcient induction of Foxp3 by trans-
forming growth factor-beta (TGF-β). These results suggest
that Treg cell development involves Dicer-generated RNAs
awaiting functional assessment. miR-31 negatively regulates
Foxp3 expression by binding directly to its potential target
site in the 3 -UTR of Foxp3 mRNA whereas miR-21 acts as
a positive, though indirect, regulator of Foxp3 expression
[117]. Finally, miR-155 inhibition sensitizes CD4+ Th cells
for Treg-mediated suppression [118].
3.2.2. B Cells. The generation of B cells that express high
aﬃnity antigen receptors involves two main stages: antigen-
independent development in the bone marrow and antigen-
dependent selection in the secondary lymphoid organs, both
of which are associated with dynamic regulation by miRNAs
[9, 119]. Antigen receptors on the surface of B cells trigger
adaptive immune responses after encountering their cognate
antigens but also control a series of antigen-independent
checkpoints during B cell development. These physiological
processes are regulated by the expression and function of
cell surface receptors, intracellular signaling molecules, tran-
scription factors, and miRNAs [119]. Temporal regulation of
several diﬀerent miRNAs was observed and putative new cell
type-speciﬁc miRNAs were identiﬁed in the development of
B cells, suggesting the involvement of many, but undeﬁned,
regulatory pathways in B cell development and maturation
[9].TheroleofmiRNAsincontrollingtheearlydevelopment
of B cells is now thought to involve the modulation of
key protein factors that control these aspects of B cell
development [97]. miR-181 is preferentially expressed in the
B-lymphoid cells of mouse bone marrow and its ectopic
expression in hematopoietic stem/progenitor cells leads to
an increased fraction of B-lineage cells, without increase of
T cells or myeloid cells in both tissue-culture diﬀerentiation
assays and adult mice [91].
In contrast, mice with a conditional deletion of Dicer
in B cells had a complete block in B cell development
[120]. This block is related to dysregulated expression of
the proapoptotic protein Bim, probably during the selec-
tion of eﬀective antigen receptors. These results suggest a
defect in the regulation of B cell selection. Regulation of
apoptosis and cell cycle progression plays an essential role
in the maintenance of B-cell homeostasis, because a ﬁne
balance of survival and expansion is critical for preventing
lymphocyticdisorders.Interestingly,thechangesobservedby
gene expression proﬁling of Dicer-deﬁcient B cell precursors
are generally similar to those observed in B cells lacking the
miR-17–92 family. Absence of miR-17–92 leads to increased
levels of the proapoptotic protein Bim and inhibits B cell
development at the pro-B to pre-B transition [121]. In
addition to eﬀects on antigen receptor selection, miRNAs
also regulate the transcription factors involved in early B
cell development [9]. Constitutive expression of miR-150,
which is highly upregulated at the immature B cell stage,
leads to a block at a proximal stage of B cell development,
the pro-B to pre-B cell transition, indicating that miR-150
most likely downregulates mRNAs that are important for6 Autoimmune Diseases
pre- and pro-B cell formation or function [96]. miR-150
controls B cell diﬀerentiation by targeting the transcription
factor c-Myb [97]. miR-125b also promotes B cell diver-
siﬁcation in the germinal center by inhibiting premature
utilization of essential transcription factors for plasma cell
diﬀerentiation [122].
The contribution of miRNAs in the antigen-driven
stages of the humoral response in secondary lymphoid
organs has also been described [9]. miR-155 is required
in B cell responses to thymus-dependent and -independent
antigens [123]. B cells lacking miR-155 generated reduced
extrafollicular and germinal center responses and failed to
produce high-aﬃnity IgG1 antibodies. When transcription
factor Pu.1 is overexpressed in wild-type B cells, fewer IgG1
cells are produced, suggesting that loss of Pu.1 regulation
is a contributing factor to the miR-155-deﬁcient phenotype
[123]. The miR-23a cluster is a downstream target of PU.1
involved in antagonizing lymphoid cell fate determina-
tion [124]. miR-155 represses activation-induced cytidine
deaminase, which is required for immunoglobulin gene
diversiﬁcation in B lymphocytes [125, 126] .Ar e c e n ts t u d y
showed that numerous miRNAs were expressed in a stage- or
transformation-speciﬁc fashion in B cells, suggesting speciﬁc
functional or pathological roles [127].
3.3. MicroRNAs in Innate Immune Responses. The innate
immune response provides the initial defense against infec-
tion by external pathogens and is predominantly mediated
v i am y e l o i dc e l l ss u c ha sm a c r o p h a g e s ,D C s ,m o n o c y t e s ,
neutrophils, as well as natural killer (NK) cells. The presence
of pathogens is commonly detected by tissue APCs such as
macrophages and DCs via families of pattern recognition
receptors that bind nonself-antigens such as microbial
products. Many families of pattern recognition receptors
have been identiﬁed, although the best characterised are the
TLR which are composed of 11 members and the interleukin
IL-1 receptors which have 10 members. On ligation, the APC
is activated by the Nuclear factor kappa B (NF-κB) pathway
that leads to the production of type 1 IFNs, including IFN-
β. These processes are stereotypical and do not generate
immunological memory. The distinction between the body’s
cells and unwanted foreign invaders becomes obscured in
autoimmune diseases. Thus, the innate immune system
plays an important role in autoimmunity. Emerging data
have identiﬁed an important contribution of miRNAs to
the development and function of innate immune cells.
Furthermore, studies investigating myeloid cell development
and function have identiﬁed a common theme of a dynamic
interplay between lineage-speciﬁc transcription factors and
miRNAs.miRNAsinvolvedintheregulationofgranulocytes,
monocytes, macrophages, DCs, NK, and natural killer T cells
have been identiﬁed [9, 98].
Several studies have shown that transcription factors
involved in monocytopoiesis are regulated by, and/or regu-
late, speciﬁc miRNAs, which indicates a connection between
these molecular species during development [9, 98]. Studies
in human umbilical cord blood CD34+ haematopoietic
progenitor cells induced to diﬀerentiate into monocytes
upon exposure to macrophage-colony stimulating factor
(M-CSF) showed that monocytopoiesis is controlled by a
circuitry involving sequentially three miRNAs (i.e., miR-
17-5p, miR-20a, and miR-106a, members of the miR-17–
92 and related miR-106a–92 families) and the transcription
factor acute myeloid leukaemia-1 (AML1) [128]. During
monocytic diﬀerentiation, the expression of these miRNAs
is downregulated, whereas the transcription factor AML1
is upregulated at the protein but not mRNA level. Accord-
ingly, this process promotes M-CSF receptor (M-CSFR)
transcription, which therefore enhances the diﬀerentiation
and maturation of monocytes. While these miRNAs target
AML1, this transcription factor binds and transcription-
ally inhibits expression of miR-17-5p, miR-20a, and miR-
106a in a mutual negative feedback loop [128]. PU.1 is
another transcription factor that is crucial for monocyte
and macrophage diﬀerentiation [129]. PU.1 activates the
transcription of miR-424, and this upregulation is involved
in stimulating monocyte diﬀerentiation through miR-424-
dependent translational repression of nuclear factor I/A
(NFI-A). In turn, the decrease in NFI-A levels is important
for the activation of diﬀerentiation-speciﬁc genes such as M-
CSFR [129]. Translational repression of NFI-A by miR-233 is
also involved in myeloid cell diﬀerentiation [95].
Neutrophils arise from granulocyte-monocyte progeni-
tors under the inﬂuence of the transcription factor growth
factor independent 1 (GfI1) [9]. GfI1 was recently shown
to bind to the promoter regions of pri-miR-21 and pri-
miR-196b and repress their expression [130]. The sustained
expression of miR-155 can increase immature granulocyte
numbers in vivo, and several of its targets, including SH2-
domain-containing inositol-5-phosphatase 1 (SHIP1), are
probably involved in this process [131, 132]. In addition to
regulating neutrophil development, miRNAs also regulate
granulocyte function. Genetic deletion of miR-223 can
positively inﬂuence myeloid cell development and function
in vivo [133]. miR-223 is induced by the myeloid transcrip-
tion factors PU.1 and CCAAT/enhancer-binding protein-β
(C/EbPβ), and it negatively regulates both the proliferation
and activation of neutrophils. Myeloid Elf1-like factor 2C
(MEF2C) has been shown to be a direct target of miR-
223. TLR4-activated NF-κB rapidly increases the expression
of miR-9 that operates a feedback control of the NF-κB-
dependent responses by ﬁne tuning the expression of a key
member of the NF-κBf a m i l y[ 134]. Brief exercise alters the
miRNA proﬁle in circulating neutrophils in humans [135].
miRNAs regulate distinct aspects of DC biology and
so are involved in the crucial connection between innate
and adaptive immune responses. miR-34 and miR-21 have
been shown to be important for human myeloid-derived DC
diﬀerentiation by targeting the mRNAs encoding Jagged1
and WNT1 [136]. Myeloid-derived DCs from Bic−/− (miR-
155-deﬁcient) mice showed defects in antigen presentation
to T cells [137]. In addition, miR-155 downregulated expres-
sion of DC-speciﬁc ICAM3-grabbing nonintegrin (DC-
SIGN; also known as CD209) by human monocyte-derived
DCs through suppression of PU.1 expression [138]. DC-
SIGN is a cell surface C-type lectin that binds pathogens,
implicating miRNAs in the regulation of pathogen uptake byAutoimmune Diseases 7
DCs. In human myeloid-derived DCs, knockdown of miR-
155 expression signiﬁcantly increased protein expression of
the proinﬂammatory cytokine interleukin-1β (IL-1β)[ 139].
miR-146a acts as a regulator of monocyte and DC activation
but not myeloid/DC subset diﬀerentiation [140].
miRNAs have been implicated in the development and
function of NK cells which are important components
of immune surveillance against cancer and viral infection
[9]. NK cells express the receptor natural killer group 2,
member D (NKG2D), which recognizes ligands, MHC
class I polypeptide-related sequence A (MICA), and MICB,
expressed by cells undergoing stress triggered by events such
asviralinfectionorcelltransformation[9,141].Engagement
ofNKG2DonNKcellsleadstodirectkillingofthetargetcell.
A recent study showed that a set of miRNAs, many of which
are overexpressed by various cancer cells, binds to MICA and
MICB 3 -UTR sequences and maintains expression of MICA
and MICB protein under a certain threshold and facilitates
acute upregulation of MICA and MICB during cellular
stres [142]. Certain herpesvirus family members, namely,
cytomegalovirus, Epstein-Barr virus and Kaposi’s sarcoma-
associated herpesvirus, produce miRNAs that target MICB
mRNA, suggesting a miRNA-based immunoevasion mecha-
nism that appears to be exploited by human viruses [143].
Lipopolysaccharide (LPS) stimulation decreased expression
of miRNAs, miR-17-5, miR-20a, and miR-93, which target
MICA, implicating a novel role for miRNAs in NKG2D
ligandexpression. These resultssuggestthatTLRstimulation
allows expression of NKG2D ligands through multiple
pathways, including downmodulation of speciﬁc miRNAs
[144]. Invariant NKT (iNKT) cells are a class of innate-
like T cells that express an invariant TCR that recognizes
lipids presented by the MHC class I-like CD1d molecule
and regulate diverse immune responses [9, 145]. Two recent
studies showed that diﬀerentiation and homeostasis of iNKT
cells require Dicer in a cell-autonomous fashion [146, 147].
Dicer deletion results in a substantial reduction of iNKT
cells in thymus and their disappearance from the periphery.
Without Dicer, iNKT cells do not complete their innate
eﬀector diﬀerentiation and display a defective homeostasis
due to increased cell death.
Numerous studies clearly demonstrate that miRNAs play
an essential role in the regulation of various aspects of
innateimmunity,includingtheregulationofdirectmicrobial
killing,theproductionofcytokines,andantigenpresentation
by MHC molecules. All of these mechanisms are important
for host defense and are instrumental in initiating antigen-
speciﬁcresponsesbycellsoftheadaptiveimmunesystem[9].
Both the induction and repression of miRNA expression
in response to inﬂammatory stimuli can inﬂuence several
biological processes and exert pro- or antinﬂammatory
eﬀects [16]. Microbial products are important proinﬂam-
matory stimuli and activation by TLR ligands has been
shown to modulate several miRNAs including miR-9, miR-
125b, miR-146a, and miR-155 [98]. Of these miRNAs, only
miR-146a and miR-155 appear to be induced in multiple
cell types. In macrophages and DCs, stimulation by TLRs
ligands results in miR-155 induction via NFκBp a t h w a y
and signalling through the c-jun-N-terminal kinase (JNK)
pathway [148, 149]. The induction of miR-155 by LPS has
also been demonstrated in vivo and is accompanied by a
decrease in miR-125b expression [149].
ThedownregulationofmiR-125bappearstobenecessary
in macrophages to prevent suppression of Tumor necrosis
factor-alpha (TNF-α) during the inﬂammatory response.
miR-155 is upregulated in murine macrophages by the
synthetic triacylated lipopeptide Pam3CSK4, the synthetic
double stranded RNA analog poly(I:C), LPS, and CpG
oligonucleotides, suggesting that several TLR ligands can
induce miR-155 expression and that miR-155 is involved in
the regulation of both bacterial and viral innate immune
responses [148]. Fas-associated death domain protein, IkB
kinase ε and receptor interacting serine-threonine kinase
1 were experimentally validated as targets of miR-155
[139, 148]. Involvement of miR-155 in the TLR-induced
antigen presentation pathway was conﬁrmed by a study
showing that miR-155-deﬁcient DCs are unable to induce
eﬃcient T-cell activation, with impaired antigen presen-
tation and costimulation [137]. miR-9 is upregulated in
both polymorphonuclear neutrophils and monocytes after
TLR4 activation. This miRNA is also induced by TLR2
and TLR7/8 agonists and by the proinﬂammatory cytokines
TNF-α and IL-1β [134]. MiR-146, miR-147, and miR-21
are also upregulated after the activation of TLR4 upon
stimulation via LPS [150–152]. However, in contrast to
miR-155, these miRNAs are negative regulators of pattern-
recognition response. miR-146a reduces the translation of
tumournecrosisfactorreceptor-associatedfactor-6(TRAF6)
and IL-1 receptor-activated kinase-1 (IRAK1), which are two
key components of the TLR signalling pathway [150]. These
studies indicate an essential role of miRNAs as important
regulators of inﬂammation.
4.MicroRNAs andAutoimmunity
The roles of miRNAs are only beginning to be explored
in the context of autoimmunity, in which they may be
involved in regulating immune responses against self-tissues
[9]. Immune responses are normally targeted against micro-
bial pathogens and not self-antigens by mechanisms that
are only partially understood. Over the past few decades,
multiple mechanisms have emerged that operate to prune
the lymphocyte repertoire of self-reactive speciﬁcities and
maintain immunological tolerance. miRNAs target immune
transcripts to ﬁne-tune gene expression and turn on negative
feedback loops. Both of these actions are crucial to limit
costimulation, set precise cellular activation thresholds, cur-
tail inﬂammation, control lymphocyte growth, and maintain
regulatoryTcellhomeostasisandsuppressivefunction[153].
miRNA expression is tightly regulated during hematopoiesis
and lymphoid cell diﬀerentiation and disruption of the
entire miRNA network or selected miRNAs may lead to
dysregulated immune responses. Dysregulation of single
or a few miRNAs or miRNA clusters can result from
genetic variation, hormonal inﬂuences, or environmental
triggers including infections. In the light of this vast and
promiscuous miRNA-mediated regulation of autoimmune8 Autoimmune Diseases
genes, it is anticipated that changes in miRNA levels or their
target sequences may help explain susceptibility to complex
autoimmune diseases. Abnormalities in miRNA expression
related to inﬂammatory cytokines, Th17 and Treg cells, as
well as B cells have been described in several autoimmune
diseases [9, 13, 14, 154].
In 2007, the involvement of miRNA in a new pathway
regulating autoimmunity was discovered in T lymphocytes
in the sanroque mouse [155]. The sanroque mouse was
originally selected from screening mutant mice derived from
the chemical mutagen N-ethyl-N-nitrosourea and has been
shown to result from a mutation in the gene Roquin that
encodes a RING-type ubiquitin ligase [14]. In normal T
cells, Roquin normally limits the expression of inducible
T-cell costimulator (ICOS) by promoting the degradation
of ICOS mRNA. In sanroque mice, however, the absence
of this regulation leads to an accumulation of lymphocytes
that is associated with a lupus-like autoimmune syndrome.
Yu et al. reported that miR-101 is required for the Roquin-
mediated degradation of ICOS mRNA [155]. Introducing
mutations into the miR-101 binding sites in the 3 -UTR of
ICOS mRNA disrupted the repressive activity of Roquin.
These results revealed a critical miRNA-mediated regula-
tory pathway that prevents lymphocyte accumulation and
autoimmunity. More recently, deletion studies showed that
targeted deletion of miRNAs in hematopoietic stem cells
or in thymus disrupts T cell homeostasis and results in
autoimmunity and abnormal cytokine production. Recent
studies revealed the importance of miRNA regulation in
safeguarding Treg function in the prevention of autoimmu-
nity. miRNA biogenesis is indispensable for the function
of Treg cells. Speciﬁc deletion of either Drosha or Dicer
phenocopies mice lacking a functional Treg cell-speciﬁc
transcription factor Foxp3 gene or Foxp3(+) cells whereas
deletion throughout the T cell compartment also results in
spontaneous inﬂammatory disease, but later in life [112].
Treg cell-mediated immune tolerance is critically dependent
on the Dicer-controlled miRNA pathway. Mice with condi-
tional Dicer knockout within the Treg cell lineage rapidly
developed fatal systemic autoimmune disease resembling the
Foxp3 knockout phenotype [110, 111]. Although thymic
Treg cells developed normally in Dicer-deﬁcient mice, the
cells exhibited altered diﬀerentiation and dysfunction in the
periphery. Interestingly, Dicer-deﬁcient Treg cells retained
some suppressive activity, albeit reduced compared to wild-
type mice [111]. However, under inﬂammatory conditions
Dicer-deﬁcient Treg cells were completely devoid of any
suppressor activity and instead showed a robust in vitro
proliferative response leading to autoimmunity suggesting
thatmiRNAspreservetheTregcellfunctionalprogramunder
inﬂammatory conditions. These ﬁndings support a central
role for miRNAs in maintaining the stability of diﬀerentiated
Treg cell function in vivo and homeostasis of the adaptive
immune system.
Furthersupportforacausalrelationshipbetweenspeciﬁc
miRNAs and the onset of autoimmunity has come from
studies involving miR-17–92 overexpression in mice [102].
Mice with higher expression of miR-17–92 in lymphocytes
developed lymphoproliferative disease and autoimmunity
and died prematurely. miR-17–92 overexpression promoted
marked lymphoproliferation, the presence of serum autoan-
tibodies, and tissue changes such as lymphoid inﬁltrates
and antibody deposition. T cells seem to develop normally
in these mice, but the number of mature CD4+ T cells
was markedly increased and they had a highly activated
proﬁle, suggesting a failure of peripheral tolerance. Lym-
phocytes from these mice showed more proliferation and
less activation-induced cell death. The miR-17–92 miRNA
suppressed expression of the tumor suppressor Phosphatase
and tensin homolog (Pten) and the proapoptotic protein
Bim [102]. This mechanism probably contributed to the
lymphoproliferative disease and autoimmunity of miR-17–
92-transgenic mice. Dysregulation of miRNAs involved in
immune cell development may cause autoimmunity. A
recent study has shown that inhibition of miR-181a in T cells
during thymic development converts endogenous positively
selecting peptides into autoantigens [156].
Emerging evidence has demonstrated that miRNAs are
diﬀerentially expressed in autoimmune diseases and miRNA
regulation may impact in the development or prevention of
autoimmunity. miRNA dysregulation is linked to autoim-
mune diseases that include rheumatoid arthritis, systemic
lupus erythematosus, primary biliary cirrhosis, ulcerative
colitis, psoriasis, Idiopathic thrombocytopenic purpura, pri-
mary Sj¨ ogren’s syndrome, and MS.
These molecules have also been shown to be useful as
diagnostic and prognostic indicators of disease type and
severity [15–17]. Many autoimmunity and disease suscep-
tibility genes are targeted by several miRNAs [153, 157].
The precise mechanisms miRNAs use to promote or hinder
autoimmunity have yet to be elucidated. However, several
potential mechanisms deserve consideration, including loss
or downregulation of miRNA expression due to mutation,
epigenetic activation, aberrant processing, or transcriptional
downregulation; overexpression of particular miRNA conse-
quent to gene ampliﬁcation or mutation, especially miRNA
promoter regions, or due to transcriptional upregulation
that may result in the suppressed production of its target
proteins; and mutation at the 3 -UTR of the target mRNA
o ri t sg e n e[ 14]. In most cases the role of speciﬁc miRNAs
in autoimmune diseases has been established in vitro by
association, and that causal roles in vivo remain a matter of
investigation [14].
Clinical characteristics along with pathological hetero-
geneitymakeMSappealingtostudymanyaspectsofmiRNAs
in an organ-speciﬁc autoimmune disease, such as their
potential as diagnostic or prognostic biomarkers and their
role in pathogenesis of autoimmunity, neuroinﬂammation,
and organ dysfunction. Thus, we will focus on the involve-
ment of speciﬁc miRNAs in MS pathogenesis following the
general overview of the immunopathobiology of the disease.
5. MicroRNAs andMultiple Sclerosis
5.1. Genetic and Epigenetic Factors in Multiple Sclerosis.
MS is a chronic inﬂammatory demyelinating disease of
the CNS that primarily aﬀects young adults. PrevalenceAutoimmune Diseases 9
rates for MS vary between 2 and 160 per 100,000 in
diﬀerent countries, and more than 2 million individuals are
aﬀected by this disease worldwide [158]. Autoreactive T cell-
mediated autoimmune response to myelin antigens results
in both inﬂammation and axonal degeneration accounting
for the disability of patients with MS [19]. The exact
factors that initiate inﬂammation are unknown, but it is
generally believed that MS is caused by environmental
factors in a genetically susceptible host that trigger a T-cell
autoimmuneresponseagainsttheCNS[18].Intheliterature,
several genetic factors have been described to inﬂuence the
development and severity of MS and are responsible for
disease susceptibility [20]. The major genetic factor in MS is
the major histocompatibility complex [159], however recent
genomewide association studies revealed new susceptibility
alleles for MS that are all related with immune functions
(e.g., CASP8, CD58, STAT3, interleukin 7 receptor (IL7RA;
CD127), interleukin 2 receptor A (IL2RA)) [20, 160, 161].
Nevertheless, no locus has been detected of constant form
in all the studies, suggesting the existence of genetic hetero-
geneity. MS is likely to be the result of interactions between
environmental stimuli (e.g., infection), susceptibility genes
(which predispose individuals to the development of neu-
roinﬂammation), and modiﬁer genes (which aﬀect disease
phenotype in susceptible subjects). Although viruses may
trigger MS relapses, there is no deﬁnitive evidence that there
isanMSvirusoranongoingchronicinfectionofthenervous
system. It is possible, however, that a self-limited CNS
infectioninchildhoodcouldtriggerMS,andepidemiological
evidence suggests that Epstein-Barr virus (EBV) may play
a key role in MS [18]. Other nongenetic but nevertheless
gene-regulation factors including epigenetic mechanisms
such as DNA methylation and histone modiﬁcation and
miRNA-mediated posttranscriptional gene regulation might
individually inﬂuence both susceptibility and severity of the
disease [162].
Experimental allergic encephalomyelitis (EAE) serves as
the primary and most widely used animal model for MS
and can be induced in susceptible rodent strains by active
immunization of myelin antigens [163, 164]. Diﬀerent types
of the model have been developed that mimic virtually all
the clinical features of MS including relapsing, relapsing
remitting, progressive, and opticospinal forms. The majority
of treatments for MS have stemmed from studies in the EAE
model, further supporting the concept that autoimmune
processes in the EAE model are relevant to MS [18].
However, there are also examples of mechanisms that have
worked in EAE but have failed in the clinic, such as the TNF-
α antagonists and anti-p40 (a subunit of IL-12 and IL-23)
[163, 164].
5.2. Immunopathobiology of Multiple Sclerosis. The clinical
course of MS varies, with 80% of patients presenting with
episodes of disability followed by a period of recovery
classiﬁed as relapsing-remitting while 10%–15% exhibit a
moreprogressivediseasewithoutremission,namely,primary
progressive [165, 166]. The patient has a yearly risk of
about 3% for a transition from the relapsing-remitting phase
to the chronic, progressive form of MS. Over a period of
10 years, roughly half of relapsing-remitting patients enter
a secondary progressive stage of disease characterized by
accumulating disability while recovery between episodes
diminishes.
There is consensus that a dysregulated immune system
plays a critical role in the pathogenesis of MS. Relapses
are driven by the adaptive immune system and involve
waves of Th1, Th17, and CD8+ cells that inﬁltrate the CNS
and provoke an attack. These cells are modulated by Treg
and B cells. MS is initiated and maintained by continuous
migration of inﬂammatory immune cells from the periphery
into the target organ. The three ways that lymphocytes can
enter the CNS include entry from the bloodstream across
the choroid plexus into the Cerebrospinal ﬂuid (CSF), from
the blood in the subanachroid space into the CSF, or directly
into the parenchyma under permissible conditions, such as
inﬂammation, controlled by cell adhesion molecules and
cytokines [167]. Subpopulations of T cells may employ
diﬀerent traﬃcking mechanisms [163]. Inﬁltration of T cells
into the CNS initiates a complex immunological cascade
consisting of epitope spreading, which triggers new attacks,
and activation of the innate immune system composed of
microglia, dendritic cells, and astrocytes [18]. The secondary
progressive phase is due to neurodegeneration triggered by
neuroinﬂammation and is driven by the innate immune
system. The loss of axons and their neurons in the course
of chronic neuroinﬂammation is a major factor determining
long-term disability in patients and neurodegeneration as
the major cause of irreversible neurological disability in MS
patients. Thus, in the relapsing stage, a proinﬂammatory
milieu that combines both the innate and adaptive immune
system is present whereas in the progressive stage abnormal-
ities of the innate immune system predominate [18].
5.2.1. Adaptive Immune Responses in Multiple Sclerosis
Pathogenic T Cells. Among cells isolated from the inﬂam-
matory inﬁltrate in actively demyelinating MS lesions,
approximately 10% are T cells [168, 169]. There, multiple
T-cell subsets have been implicated: CD4+ Th1 and Th17,
γ/δ T cells, CD8+, and Treg cells [163]. CD4+ T cells are the
most prominent cells in active MS lesions but are not present
in chronic MS lesions [170]. It is generally believed that the
acute MS lesion is initiated by a myelin-reactive CD4+ T cell
that is stimulated in the periphery and enters the brain and
spinal cord [18]. Recent research has focused on the diﬀerent
rolesofsubsetsofCD4+TcellsinMSandotherautoimmune
diseases.Th1cellsclassicallyexpressIFN-γ,TNF -β,IL -2,and
nitricoxide[171]andactivatemacrophagestostimulatecell-
mediated immunity [168]. Th2 cells release IL-4, IL-5, IL-
6, IL-10, IL-13, and TGF-β [168]. These cytokines may be
associated with disease recovery in MS. Th17 cells are CD4+
Tcellssubtypethatareassociatedwithautoimmunediseases.
Th17 cells are dependent on IL-23, TGF-β,I L - 6 ,a n dI L -
1[ 163]. Th17 cells produce IL-17A and IL-17F, which are
upregulated in chronic lesions [172, 173], and IL-22 which
is also involved in MS pathogenesis. It is now recognized that10 Autoimmune Diseases
Th17 cells play a crucial role in autoimmunity in the EAE
model [174]. However, recent work by Haak et al. [175]h a s
demonstrated that overexpression of IL17 in T cells did not
exacerbate EAE. If Th17 cells are given with Th1 cells, then
full disease induction occurs [176]. These results suggested
that pure Th17 cells are not pathogenic. Both types of cells
(Th1 and Th17) may play a role in MS and could account for
the immunological and clinical heterogeneity of the disease
[18, 177].
Most TCRs are composed of two linked polypeptides,
α and β, which participate in the recognition of foreign
antigen plus self-MHC [168, 178] .H o w e v e r ,as m a l ls u b t y p e
of circulating lymphocytes expresses γ/δ TCR polypeptides
which function in both innate and adaptive immunity [168,
179]. Clonal expansion of activated lymphocytes bearing
the γ/δ TCR has been demonstrated in samples isolated
from the CSF of patients with recent-onset MS but not
from patients with chronic MS [180]. Recently, investigators
demonstrated that γ/δ T cell-deﬁcient mice were unable to
recover from EAE [168, 179, 181]. Histopathologically, there
w a sap r o l o n g e dp r e s e n c eo fm o n o c y t e sa n dl y m p h o c y t e s
in the CNS [179, 181]. CD8+ T cells are also implicated in
MS pathology. Within MS plaques, clonal and oligoclonal
expansion of CD8+ T cells reactive to myelin antigens has
been observed [182]. A new eﬀector T cell subset, Th9 cells,
has been identiﬁed. Jager et al. showed that Th9 eﬀector
cells participate in induction of EAE [183]. These results
suggested that Th9 cells may participate in MS pathogenesis.
Regulatory T Cells. Defects in Treg-cell function have been
described in MS, and a major goal of MS immunotherapy
is to induce regulatory cells in a physiological fashion [184–
186]. Clinical studies in MS patients showed that Treg cell
dysfunctionoccurredintheinitialstagesofthedisease[168].
In addition, experimental data suggest that regulatory cells
may not be eﬀective if there is ongoing CNS inﬂammation
[187].
B Cells and Antibodies. MS is generally thought to be
a T cell-mediated immune disease although there is an
important role of humoral immunity in pathogenesis of MS.
Intrathecal antibody synthesis is a hallmark of the disease
process and, in most of cases, consists of oligoclonal IgG
production [18, 188]. A direct correlation has been reported
between levels of immunoglobulin production and MS
disease severity [189, 190]. Antibodies to self-antigen such
as Myelin Basic Protein (MBP) and myelin oligodendrocyte
glycoprotein (MOG) have been identiﬁed in the serum of
patients with MS and clinically isolated syndromes (CISs)
[191, 192]. B cells and plasma cells have been detected in
brains and CSF of patients with MS [189]. Characterization
of the B-cell compartment within the CSF of MS patients
shows that short-lived plasmablasts, not plasma cells, are the
predominant antibody-secreting cell in MS CSF [189, 193]
and the B cell to monocyte ratio correlates with the rate
of disease progression. B cells are also potent APCs and
may play a prominent role in T-cell antigenic stimulation.
Thus, B cells may well be active participants in initiating and
maintaining disease [168].
5.2.2. Innate Immune Responses in Multiple Sclerosis. The
innate immune system consists of monocytes, dendritic
cells, and microglia. The innate immune system plays an
important role in the immunopathogenesis of MS. The
secondary progressive phase of MS has been believed to
be related to neurodegenerative changes in the CNS [18].
Furthermore, chronic microglial activation occurs in MS
[194]. The peripheral innate immune system changes cause
thetransition fromtherelapsing-remitting totheprogressive
stage. This raises important questions regarding the patho-
genesis and treatment of diﬀerent stages of MS. A major
question is whether aggressive and early anti-inﬂammatory
treatment will prevent the secondary progressive form of the
disease. There are no speciﬁc therapies designed to aﬀect the
innate immune system in MS. Furthermore, like the adaptive
immune system, there are diﬀerent classes of innate immune
responses, for example, protective and tolerogenic versus
pathogenic and proinﬂammatory [18]. This fact should be
kept in mind for new drug development studies that target
innate immunity.
Antigen Presenting Cells. Macrophages are the major MHC
Class II positive cell in the CSF. Macrophages in EAE
have an integral role in initiating disease, and deple-
tion of macrophages signiﬁcantly inhibits disease [195].
Macrophages are not the only class II positive cells that can
present myelin antigens. Monocytes, DCs, microglia, and
astrocytes have all been implicated in presenting antigen and
involved in MS pathogenesis [163]. Greter et al. demon-
strated that mice with MHC class II expression limited to
DC can still develop disease [196]. DCs can be further
subdivided into myeloid (mDCs) and plasmacytoid DCs
(pDCs) depending on their lineage, and they also diﬀer in
function [163]. pDCs are the major CNS-inﬁltrating DC
population duringEAEandpDCshavebothstimulatoryand
regulatory eﬀects on T cells [197]. pDCs negatively regulate
CD4+ inﬂammatory responses in the CNS [197]. Depletion
of pDCs during either the acute or relapse phase of EAE
resulted in exacerbation of disease severity [163]. In MS
patients, pDC from peripheral blood showed an immature
phenotype. The pDC had a lower capacity to secrete IFN-
α upon TLR-9 stimulation. This may indicate why common
infectious agents trigger MS attacks [198]. mDCs within the
CNS activate myelin speciﬁc T cells that are recruited to the
inﬂamed tissue and facilitate diﬀerentiation into Th1 and
Th17 cells [199, 200]. However, Deshpande et al. reported
that mDC isolated from the peak of disease are less eﬃcient
APCs than those isolated at disease onset, suggesting that
changes in DC phenotype may contribute to remissions
[200].
Microglial cells seem to be crucial for maintaining
autoimmuneresponsesintheCNS.Ithasbeendemonstrated
that both a microglial cell-speciﬁc deﬁciency of CD40
expression and a transient inactivation of microglial cells
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Astrocytes also express MHC Class II after IFNγ expo-
sure and it has been reported that astrocytes can present
antigen [202]. Astrocytes from mice deﬁcient in Class II
transactivator(CIITA)failedtoactivateMOG-speciﬁcCD4+
T cells due to a lack of MHC Class II expression [163,
203]. However, CIITA-deﬁcient mice still were susceptible
to EAE [203]. However, human astrocytes do not eﬀectively
activate encephalitogenic T cells in vitro [204]. They may
also inﬂuence the disease by secretion of cytokines and
chemokines.
5.3. Neurodegeneration in Multiple Sclerosis. The identiﬁca-
tion of MS susceptibility loci, of which at least 15 have a
primary function in immunological systems, favors early
immune dysregulation followed by secondary neurodegen-
erative processes [163]. Indeed, MS is not exclusively a white
matter disease. Speciﬁc cognitive deﬁcits such as memory
impairment, attention deﬁcit, and reduced mental reasoning
are increasingly being explained by damage to neurons in
the gray matter, which aﬀects 45%–65% of MS patients
[205]. Although the precise trigger for MS remains elusive,
it is understood that autoimmune mechanisms underlie the
pathology, and furthermore that activated T cells migrate
through the BBB where they accumulate and proliferate
because of antigen restimulation. These cells release a host of
proinﬂammatory molecules, which, in turn, further activate
microglia or inﬁltrated macrophages and B cells. Axonal
and neuronal injury occurs as an early event in the disease
and is strongly correlated with the degree of inﬂammation
in the brain [206–208]. In MS, neurons in the cortex
and spinal cord are also aﬀected, albeit to varying extents
[209, 210]. The latest events in the chain of neuronal
damage processes following focal axonal lesions include
axon degeneration and atrophy of neuronal cell bodies and
dendrites [165]. The loss of neurons and their processes is
the leading cause of atrophy and is the primary determinant
of long-term disability in MS patients. This chain of events
produces a marked inﬂammatory response, which causes
axonal injury through various antigen speciﬁc and bystander
mechanisms.
In MS, both soluble factors and surface molecules
could participate in neurodegeneration. Besides injurious
proinﬂammatory molecules, proapoptotic factors produced
by T cells, including FasL, granzyme B, soluble TNF-
related apoptosis-inducing ligand (TRAIL), glutamate, nitric
oxide, and free radicals, are possible mediators of injury
[208, 211–214]. Accumulating evidence suggests that the
increased energy demand of impulse conduction along
excitable demyelinated axons and reduced axonal ATP
production induce a chronic state of virtual hypoxia in
chronically demyelinated axons, ultimately leading to exces-
sive stimulation of Ca2+-dependent degradative pathways
[215]. Glutamate and nitric oxide can lead to enhanced
expression of chemokine (C-C-motif) ligand 2 (CCL2) on
astrocytes, which, in turn, leads to inﬁltration of CD11b
cells and additional tissue damage [216]. Antiexcitotoxic
compounds have an ameliorating eﬀect in EAE model [18].
Another important component of neurodegeneration relates
to changes in Na+ channels, and these are targets of therapy
[217].
Axonal injury can be directly caused by immune cells.
CD4+ and CD8+ T-cell subsets, once activated, are highly
neurotoxic. These eﬀects are mediated through a variety
of contact-dependent mechanisms involving cell surface
molecules such as FasL, LFA-1, and CD40. Th1 and Th17
proinﬂammatory classes of CD4+ T cells are neurotoxic
whereas the anti-inﬂammatory Th2 subset is not [218].
Although activated T cells can clearly harm neurons, the
converse has also been observed. Activated T cells underwent
apoptosis that was mediated through neurons via a FasL-
dependent mechanism [219]. In another context, neurons
may induce encephalitogenic T cells to convert to T-
regulatory cells that inhibit encephalitogenic T-cell action
and suppress EAE [220]. It is likely that the adaptive
immune system orchestrates the attack against CNS cells and
drivesmicrogliaandmacrophagestoattackoligodendrocytes
and neurons. Activated microglia and peripherally derived
macrophagesareshiftedtowardsastronglyproinﬂammatory
phenotype and produce apoptosis-inducing molecules such
astheTRAILandtheproinﬂammatorycytokines TNF-αand
IL-1β as well as potentially neurotoxic substances including
nitric oxide, oxygen radicals and proteolytic enzymes [221,
222].
5.3.1.NeurodegenerationandMicroRNAs. Manyrecentstud-
ies provide a link between miRNA function and neurode-
generation [223–225]. Complete loss of miRNA expression
in the brain leads to neurodegeneration in several animal
models. Evidence from patient material is emerging that
miRNA dysregulation could, indeed, contribute to neurode-
generative disorders. The translation of proteins previously
implicated in familial forms of disease seems to be under
control of miRNAs, and changes in miRNAs might explain
how these proteins become aﬀected in sporadic neurodegen-
eration. Thus, miRNAs are rapidly moving to center stage
as key regulators of neuronal development and function as
well as important contributors to neurodegeneration. The
link between miRNAs and axonal neurodegeneration in the
context of MS has not been focused on to date.
Endogenous tissue repair mechanisms such as myelin
repair, gliogenesis, and neurogenesis in MS may also be
modulated by speciﬁc miRNAs. Enhancing such repair
mechanisms is an important, and increasingly realistic, ther-
apeuticgoalinMS[226].Neurogenesisisdeﬁnedasaprocess
that includes the proliferation of neural stem/progenitor
cells (NPCs) and the diﬀerentiation of these cells into new
neurons that integrate into the existing neuronal circuitry.
Recent studies point to the importance of miRNAs in
regulating lineage-speciﬁc gene expression and determining
neuronal identity during neurogenesis [227, 228]. These
new observations suggest that miRNAs could function at
many levels to regulate self-renewal of neural stem cells
and neuronal fate speciﬁcation, implicating miRNAs in the
complexity of neurogenesis. miRNAs are also involved in
adult neurogenesis which may imply the possible role of
some miRNAs in endogenous repair mechanisms in MS12 Autoimmune Diseases
[229, 230]. In addition, cross talk between miRNA and
epigenetic regulation contributes to the modulation of adult
neurogenesis [231]. The modulation of miRNAs involved in
adultneurogenesismaystimulatethediﬀerentiationofNPCs
into mature neurons that can replace neurons lost through
the disease process in MS. Patient studies also suggest the
presence of neuronal precursor cells in MS lesions [232].
Within the CNS, myelin is produced by oligodendro-
cytes. Developmentally, the oligodendrocyte lineage arises
from subventricular zone progenitors that give rise to
oligodendrocyte progenitor cells (OPCs), which divide and
migrate throughout the CNS before terminally diﬀerenti-
ating to generate mature oligodendrocytes which myelinate
receptive axons [233]. Each step of progression along the
lineage is under tight transcriptional control; elucidation
of this control is vital for understanding developmental
myelination and for developing strategies to promote repair
in demyelinating diseases.
Remyelination following CNS demyelination restores
rapid saltatory conduction of action potentials and con-
tributes to the maintenance of axonal integrity [234].
Chronic demyelination predisposes axons to atrophy, an
irreversible event that is a major pathological correlate of
progressive functional decline. Remyelination in MS is in
most cases insuﬃcient, leading to irreversible disability.
Diﬀerent and nonexclusive factors account for this repair
deﬁcit [235]. Local inhibitors of the diﬀerentiation of OPCs
might play a role as well as axonal factors impairing the
wrapping process. Alternatively, a defect in the recruitment
of OPCs toward the demyelinated area may be involved
in lesions with oligodendroglial depopulation. Deciphering
the mechanisms underlying myelin repair success or failure
should open new avenues for designing strategies aimed at
favoring endogenous remyelination [235]. The few treat-
ments that are available for combating myelin damage in
MS, which largely comprise anti-inﬂammatory drugs, only
show limited eﬃcacy in subsets of patients. More eﬀective
treatment of myelin disorders will probably be accomplished
byearlyinterventionwithcombinatorialtherapiesthattarget
inﬂammation and other processes—for example, signaling
pathways that promote remyelination [236]. However, the
integration of these pathways with transcriptional and post-
transcriptional regulatory networks is not fully understood.
The interplay of transcription factors and epigenetic modi-
ﬁers including histone modiﬁcations, DNA methylation, and
miRNAs during development is essential for the acquisition
of speciﬁc cell fates [237]. Recent studies have identiﬁed a
number of new transcriptional regulators and miRNAs as
having key roles in oligodendrocyte (OL) diﬀerentiation and
CNS myelination, providing new targets for myelin repair
[233].
Selective deletion of miRNA-processing enzyme, Dicer,
in oligodendrocyte lineage cells results in severe myelinating
deﬁcits despite an expansion of the oligodendrocyte pro-
genitor pool [238, 239]. Dugas et al. identiﬁed the miRNA
pathways responsible for myelination using Dicer1-deleted
transgenic mouse model [238]. In this study, they found the
inhibitionofOPC-OLmiRNAprocessingresultingindefects
in mature miRNA processing. They also identiﬁed three
miRNAs: miR-219, miR-138, and miR-338. Of these miR-
NAs, miR-219 is important for OL diﬀerentiation, directly
repressing PDGFRalpha, Sox6, FoxJ3, and ZFP238 which
promote OPC diﬀerentiation [238]. Postnatal Dicer ablation
in mature OLs results in inﬂammatory neuronal degenera-
tion through increased demyelination, lipid accumulation,
and peroxisomal and oxidative damage and therefore indi-
cates that miRNAs play an essential role in the maintenance
of lipids and redox homeostasis in mature OLs [240]. A
small subset of miRNAs (e.g., miR-9, miR-23, miR-206,
miR-219, miR-338, and miR-17-92 cluster), is important
to orchestrate the switch from OPCs to myelin-forming
oligodendrocytes [238–244]. Transcription factors, myelin
proteins, signaling molecules, and cytoskletal proteins were
identiﬁed as validated targets of these miRNAs. Interestingly,
the highest diﬀerentially expressed miRNAs demonstrated
a similar pattern of expression throughout all stages of
diﬀerentiation, suggesting that they potentially regulate a
common target or set of targets in this process [245].
Dysfunction of the BBB is a major hallmark of MS
and may impair tissue homoeostasis, which may have
eﬀects on disease progression, repair mechanisms, and drug
delivery [246–248]. Thus, restoration of BBB permeability
may help endogenous tissue repair. Although the pivotal
role of miRNAs in angiogenesis is well established [249–
251], these molecules have not been focused on in the
context of MS, BBB integrity, and cerebral angiogenesis.
Only one study showed that a proapoptotic miRNA, miR-
15a,wasdownregulatedbyperoxisomeproliferator-activated
receptor delta in brain endothelial cells [252]. Peroxisome
proliferator-activated receptor delta is a nuclear receptor
whose agonists have been shown to inhibit EAE [253–
255]. However, the contribution of vascular protection by
peroxisome proliferator-activated receptor delta through
miRNA regulation in the recovery process is not known.
5.4. MicroRNA Studies in Multiple Sclerosis. Little is known
about what drives the diﬀerential control of the immune
system in MS patients compared to unaﬀected individu-
als. Thus, it is important to reveal the aberrant miRNA
expression proﬁling in MS patients. To our knowledge there
have been only seven publications investigating the role of
miRNAs in MS, six of which focus on the immune system
in MS and the other on active and inactive MS lesions
(Table 2). Diﬀerences in miRNA expression patterns have
been documented in MS compared to healthy controls and
in relapse versus remission of the disease.
Studies in peripheral blood mononuclear cells (PBMCs)
of patients with MS revealed diﬀerent expression patterns
compared to control individuals. Using qPCR, a pilot study
of the expression of 346 miRNAs in PBMCs obtained from a
small number of MS patients during relapse and remission,
versus healthy controls, demonstrated diﬀerences in gene
expression patterns not only between the MS patients and
healthy controls but also between patients with and without
active disease [256]. Two miRNAs (miR-18b and miR-599)
have been shown to be associated with relapse whereas
another miRNA (miR-96) was found to be involved inAutoimmune Diseases 13
the remission of the disease. The genes targeted by miR-96
are involved in immunological pathways such as interleukin
signaling and other pathways as wnt signaling [256]. In
another recent study, Keller et al. [257] investigated the
expression proﬁles of 866 human miRNAs; in whole blood
cells of MS patients 165 miRNAs were identiﬁed that were
signiﬁcantly up- or downregulated in patients with RRMS
as compared to healthy controls. The best single miRNA
marker, miR-145, allowed discriminating MS patients from
controls with a speciﬁcity of 89.5%, a sensitivity of 90.0%,
and an accuracy of 89.7%. The authors concluded that single
miRNAs, and even more so miRNA expression proﬁles, may
have the potential to serve as diagnostic biomarkers for
RRMS. However, MS patients in that study were treated with
either glatiramer acetate or interferon-beta while one patient
was not treated with anything. One of the diﬃculties of
studying MS is the acquisition of samples unaﬀected by the
inﬂuence of immunomodulatory treatment. These studies
do not provide information about miRNA expression in
various cell subpopulations and their importance during the
diﬀerentiation and activation of lymphocytes in MS.
The recent study by Du et al. [258] identiﬁed a Th17
cell-associated miRNA, miR-326, as a major determinant of
MS in a Chinese population but not of neuromyelitis optica.
Its expression was highly correlated with disease severity in
patients with MS and mice with EAE. In vivo silencing of
miR-326 resulted in fewer Th17 cells and mild EAE, and
its overexpression led to more Th17 cells and severe EAE.
Du et al. also found that miR-326 promoted Th17 diﬀer-
entiation by targeting Ets-1, a negative regulator of Th17
diﬀerentiation [258, 259]. These results suggest a critical
role for miR-326 in the regulation of Th17 diﬀerentiation
and the pathogenesis of MS. Although a more recent study
did not identify any statistically signiﬁcant change in whole
blood miR-326 expression between MS patients and controls
[260], one of the three most upregulated miRNA detected
in active MS lesions is miR-326 lending further support to
the relevance of this miRNA for MS pathogenesis [261]. The
discrepancies between the results of clinical studies may be
caused by diﬀerences observed in MS patients from Asian or
Caucasian origin [260]. In a group of MS patients in relapse,
glucocorticoid treatment downregulates miR-326 expression
indicating that this miRNA is under control of disease-
modifying drugs and thus may be used in the monitoring of
therapy responses [258]. Further exploration of the function
of miR-326 in other cell types may be of great importance for
understanding the immunopathogenesis of MS.
Although it is known that speciﬁc miRNAs are involved
in each step of the maturation of pluripotent hematopoietic
stem cells into the various blood cell lineages including B
and T cells [262], little is known about miRNA involvement
in the diﬀerentiation during T-cell activation under disease
conditions such as MS. A recent study has analyzed the
expression of 365 miRNA and revealed diﬀerent miRNA
expression proﬁles in CD4+, CD8+, and B cells of peripheral
blood from eight RRMS patients compared with ten healthy
volunteers and they have also validated miRNA in CD4+
cells with qPCR [263]. Importantly, all the patients had
no immunomodulatory or other MS speciﬁc treatments in
the six months before or during the study. Ten miRNAs
in CD4+, four miRNAs in CD8+, and six miRNAs in B
cells were diﬀerentially expressed in MS patients. Lindberg
et al. found distinct and cell-speciﬁc expression patterns
of miRNA in all cell subpopulations, which is well in line
with reports about diverse miRNA expression in immune
cells. Furthermore, the expression of potential target genes
of these miRNA was altered. miR-17-5p, which is known
to be involved in the development of autoimmunity and in
numerous lymphoproliferative diseases [264], was detected
in CD4+ lymphocytes of MS patients [263]. Functional
experiments with a synthetic inhibitor of miR-17 also
supported the link between miRNA expression and the
altered target gene expression. Moreover, authors have found
that miRNAs were also diﬀerentially expressed in the two
study groups following in vitro stimulation of CD4+ T
cells with anti-CD3/CD28. miR-17-5p and miR-193a were
strongly upregulated, in contrast to the downregulation of
miR-497, miR-1, and miR-126. This was correlated with
alterations in the expression of potential target genes of
miR-17-5p, that is, phosphatase and tensin homology and
phosphatidyl-inositol-3-kinase regulatory subunit 1, which
were downregulated upon stimulation of CD4+ cells in vitro.
Other deregulated miRNAs did not respond to the stimu-
lation probably due to other, non-T-cell activation related,
mechanisms in their mode of action. These results support
the role of miRNA-dependent regulatory mechanisms in the
immunopathogenesis of MS. However, in a larger and more
recentstudy,Coxetal.showedthatmiR-17isunderexpressed
in MS whole blood [260]. This discrepancy between the
studies may be due to methodological diﬀerences. Another
cause of the discrepancy may be the material analyzed in
those two studies, such as cell types. Patient number and
disease activity status may also change the outcome of the
analyses. In the study by Cox et al., the transcriptome of
currently known miRNAs was investigated using miRNA
microarray analysis in peripheral blood samples of 59 MS
patients that were free of disease modifying therapy for at
least 3 months before the study and 37 healthy age-matched
controls. Of the patients, 18 had a primary progressive,
17 a secondary progressive, and 24 a relapsing remitting
disease course. In all MS subtypes miR-17 and miR-20a were
signiﬁcantly underexpressed in MS, conﬁrmed by qPCR.
It was demonstrated that these miRNAs modulate T cell
activationgenesinaknock-inandknock-downTcellmodel.
The same T cell activation genes are also upregulated in MS
wholebloodmRNA,suggestingthatmiR-17andmiR-20aare
implicated in the development of MS [260].
It is known that Tregs play a key role in the autoimmune
balance and their improper function may facilitate the
expansion of autoreactive T cell clones. CD4+CD25+Foxp3+
Treg cells play a pivotal role in the maintenance of self-
tolerance and controlling autoimmunity [109].
Recent evidence has been provided for a potential
functionaldefectofCD4+CD25+Foxp3+ Tregcellsinpatients
with RRMS [265]. The fact that ablation of miRNAs in Treg
cells completely phenocopies the loss of Foxp3 cells clearly
indicated that multiple immunosuppressive mechanisms
used by Treg cells are ultimately controlled by miRNAs14 Autoimmune Diseases
[109]. The miRNA expression proﬁle in Treg cells from
treatment naive RRMS patients has recently been analyzed
by De Santis et al. [266]. The suppressive capacity of isolated
CD4+CD25+ has been veriﬁed by in vitro suppression assays.
When the expression levels of 723 human miRNAs were
compared in CD4+CD25+ T cells obtained from 12 MS
patients and 14 healthy donors using microarray assay, 23
human miRNAs were diﬀerentially expressed between study
groups. Among the deregulated miRNAs, members of miR-
106b-25 were found to be downregulated in the Treg cells
of MS patients when compared to healthy donors as con-
ﬁrmed by qPCR. Unexpectedly, in a preliminary experiment
performed in a very small number of subjects, the ratio
between Treg cells (CD4+CD25+CD127DIM)/T eﬀector cells
(CD4+CD25+CD127high) showed an enrichment of these
miRNA in Treg cells derived from patients as compared
to healthy controls [266]. miR-106b and miR-25 modulate
the TGF-beta signaling pathway through their action on
cell cycle inhibitor CDKN1A/p21 and the proapoptotic gene
BCL2L11/Bim. TGF-β is involved in Treg cell diﬀerentiation
and maturation [267]. Therefore, the deregulation of this
miRNA cluster may alter Treg cell activity during the course
of MS, by altering TGF-β biological functions.
Ar e c e n tin situ and in vitro study extends the current
concepts of MS lesion activity to the level of miRNA-
regulated gene expression and may have broad implications
for the regulation of macrophage activation in autoimmune
and inﬂammatory diseases in general [261]. In the study
which used laser capture microdissection from active and
inactive MS lesions to pool single cells and in vitro cultures,
diﬀerentially expressed miRNAs were assigned to speciﬁc
cell types by qPCR. Tissue specimens were obtained from
the brains of 20 MS pateints and nine control subjects
without any known neurological disease. In active MS
lesions 20 miRNAs, including those that are associated
with immune responses such as miR-155 and miR-146a,
were at least twofold more abundant and eight miRNAs
were at least twofold less abundant than in normal white
matter. Eight of the active MS brain specimens are derived
from MS cases with a very fulminant disease course called
Marburg’s variant. Some miRNAs were more prominently
regulated in Marburg’s variant than those in the other
active MS lesions, probably reﬂecting the more intense tissue
destruction in Marburg’s variant. In inactive MS lesions,
22 miRNAs were at least twofold more abundant and 13
miRNAs at least twofold less abundant than in normal
white matter. Among the signiﬁcantly altered miRNAs, some
showeddiﬀerentialregulationinactiveversusinactivelesions
whereas others were modiﬁed in the same direction. Junker
et al. found that three of the most upregulated miRNAs
in active MS lesions, namely, miR-155, miR-326, and miR-
34a, target CD47, which was one of the downregulated
transcripts in the active lesions in comparison to normal
brain white matter. CD47 is a membrane glycoprotein
and mediator of macrophage inhibition via its receptor
signal-regulatory protein alpha on myeloid cells. Using laser
dissection microscopy combined with qPCR, CD47 gene
expression was found to be downregulated in the center
of chronic active and inactive MS lesions [268]. CD47
has been considered as a “don’t eat me signal” and its
reduction in brain cells of MS could promote phagocytosis
of myelin by macrophage activation. Active MS lesions are
deﬁned by the presence of myelin degradation products
in macrophages, and phagocytosis of myelin by activated
macrophages/microglia is a crucial step in tissue destruction
in MS. The results of the study by Junker et al. suggest
that miRNAs dysregulated in MS lesions reduce CD47 in
brain resident cells, releasing macrophages from inhibitory
control, thereby promoting phagocytosis of myelin [261].
This mechanism may have broad implications for miRNA-
regulated macrophage activation in inﬂammatory diseases.
Altered miRNA proﬁles detected in MS active lesions
may reﬂect the presence of inﬁltrating immune cells, changes
in brain resident cells such as glial cells, or both. MiRNA
proﬁling in isolated cells by laser capture microdissection
from active and inactive MS lesions showed that the most
prominently upregulated miRNAs in active MS lesions, miR-
155, miR-650, miR-34a, and miR-326 were detected in
both microdissected astrocytes and inﬁltrating immune cells
[261]. Novel techniques that allow detection of miRNAs
and their targets at the same tissue sections may be used
to conﬁrm these results [269, 270]. Under in vitro culture
conditions, human astrocytes contained all 10 miRNA
that were most strongly upregulated in active MS lesions,
including miR-155, which is known to modulate immune
responses in diﬀerent ways but so far had not been assigned
to CNS resident cells [104, 137, 271, 272]. When cultured
astrocyteswerestimulatedwithvariouscytokines(i.e.,IL-1β,
TNF-α,I F N γ,a n dT G F - β), miR-23a, miR-146a, and miR-
155 were strongly induced in vitro [261]. These results were
also conﬁrmed with cultured astroglial cells from miRNA-
155−/−lacZ mice expressing lacZ reporter instead of miR-155
[104, 261].
Although Junker et al. have focused on only three
upregulated miRNAs in active MS lesions (i.e., miR-155,
miR-326, and miR-34a) and their common target CD47,
other upregulated miRNAs, especially miR-146a and miR-
34a deserve further mention. These miRNAs are known to
modulate immune responses in diﬀerent ways. They are also
implicated in other CNS disorders accompanied by chronic
neuroinﬂammatory conditions such as epilepsy, Alzheimer’s
disease (AD), and schizophrenia. miR-34a upregulation was
determinedinperipheralbloodcellsofsporadicADpatients,
cerebral cortex of APPswe/PSDeltaE9 mice, and prefrontal
cortex of schizophrenic patients [273–275]. Cortical expres-
sion of miR-34a was inversely correlated with the protein
level of Bcl2 in a double transgenic mouse model of AD.
In vitro experiments in SH-SY5Y neuronal cells veriﬁed
anti-apoptotic gene bcl2 as a target of miR-34a [274]. The
meaning of these results in the context of MS is currently
unknown. Interestingly, mood stabilizators such as lithium
and valproate modulate the expression level of miR-34a both
in vitro and in vivo [262, 276, 277]. Metabotropic glutamate
receptor 7, which is an important regulator of glutamatergic
function and of fear, aversion, and cognition, was identiﬁed
as a target of miR-34a [277, 278]. Although changes in miR-
34a expression levels are in opposite directions (downreg-
ulation in rat hippocampus and upregulation in culturedAutoimmune Diseases 15
Table 1: miRNA in immune functions.
miRNA Expressing cells Functions Targets
Let-7e macrophages Innate immune response TLR4
miR-9 myeloid cells Immune response NFK B1
miR-17-5p myeloid cells monocyte proliferation and diﬀerentiation RUNX1
miR-17-92 B and T cells B and T cell development BIM, PTEN
miR-21 myeloid cells macrophage activation IL12a, PTEN, PDCD4
miR-34 DC and B cells Myeloid DC diﬀerentiation FOXP1, JAG1, WNT1
miR-125b monocyte Innate immune response, TLR signaling TNF-α
miR-126 HSC expansion of progenitor cells HOXA9, PLK2
miR-132 monocyte Innate immune response not determined
miR-142 Treg cell Suppresor function of Treg cells AC9
miR-146a monocyte Innate immune response, TLR signaling IRAK-1, IRAK-2, TRAF6
miR-150 B and T cells mature B-cell production, T-cell activation Myb
miR-155 B and T cells, DC
Innate and adaptive immune response AID, BACH1, CEBPB,
CSFR
macrophages germinal center response c-MAF, FADD, IKK,
JARID2,
Ig G class-switch PU.1, Ripk1, SOCS, TAB2
Peripheral T cell development
miR-181a T cells T cell receptor signaling AID, BCL2, CD69, DUSP5
B cell development DUSP6, PTPN22, SHP2
miR-181b macrophages, B cells B cell class switch AID
miR-196b HSC Hematopoietic stem-cell homeostasis HOX
miR-223 myeloid cells Granulopoiesis MEF2C
miR-326 T cells TH-17 cells development ETS1
miR-424 myeloid cells monocyte diﬀerentiation and maturation NFIA, PU.1
AC9: adenylate cyclase 9; AID: Activation-Induced Cytidine Deaminase; BACH1: BTB and CNC homology 1, basic leucine zipper transcription factor
1; BCL2: B-cell lymphoma 2; BIM: BCL2-like 11; CEBPB: CCAAT/enhancer-binding protein beta; CSFR: Colony stimulating factor receptor; c-MAF:
musculoaponeurotic ﬁbrosarcoma oncogene homolog; DC: dendritic cell; DUSP5: Dual speciﬁcity protein phosphatase 5; DUSP6: Dual speciﬁcity protein
phosphatase 6; ETS1: v-ets erythroblastosis virus E26 oncogene homolog 1; FADD: Fas-Associated protein with Death Domain; HSC: haematopoetic stem
cell; HOX: Homeobox protein; HOXA9: Homeobox protein Hox-A9; FOXP1: Forkhead box P1; IKK: inhibitor of NF-kappaB kinase; IL12a: Interleukin-
12 subunit alpha; IRAK-1: Interleukin-1 receptor-associated kinase 1; IRAK-2: Interleukin-1 receptor-associated kinase 2; JAG1: jagged 1; JARID2: Jumonji;
Myb: Myb oncogene-like; MEF2C: Myocyte-speciﬁc enhancer factor 2C; NFIA: Nuclear factor 1 A-type; PDCD4: Programmed cell death protein 4; PTEN:
phosphatase and tensin homolog; PLK2: pololike kinase 2; PTPN22: Tyrosine-protein phosphatase non-receptor type 22; PU.1: spleen focus forming virus
(SFFV) proviral integration oncogene spi1; Ripk1: Receptor-interacting serine/threonine-protein kinase 1; RUNX1: Runt-related transcription factor; SHP2:
SH2 domain containing protein thyrosine phosphatase; SOCS: Suppressor of cytokine signaling; TAB2: TAK1-associated binding protein 2 TRAF6: TNF
receptor associated factor-6; TLR: Toll-like receptor; WNT1: wingless-related MMTV integration site 1.
lymphoblastoid cells) [262, 277], these results suggest that
miRNAs and their predicted eﬀectors may be targets for the
action of psychotherapeutic drugs.
miR-146a has been recently identiﬁed as a potentially
endogenous regulator of TLR and cytokine receptor sig-
nalling, suggesting a link between miRNAs and human
inﬂammatorydiseases[279].Incontrasttotheemergingrole
of miR-146a in innate immunity, a role of this miRNA in
the adaptive immune response has recently been identiﬁed.
MiR-146a is among the most highly expressed miRNAs
in murine Tregs, thus suggesting a possible role for miR-
146a in maintaining diﬀerentiated T-cell lineages [116].
miR-146a modulates activation-induced cell death (AICD),
acting as an antiapoptotic factor, and it is known that
Fas-associated death domain (FADD) is a target of miR-
146a [280]. Furthermore, miR-146a-enforced expression
impairs both activator protein 1 (AP-1) activity and IL-2
production induced by TCR engagement, suggesting a role
of this miRNA in the modulation of adaptive immunity.
NF-κB and c-ETS binding sites were identiﬁed as required
for the modulation of miR-146a transcription upon TCR
engagement.
Recently, speciﬁc miRNAs have been shown to be
signiﬁcantly upregulated in response to cytokine stress and
in aﬀected regions of AD brain. The brain-enriched miRNA-
146aiscurrentlythoughttobeakeyregulatoroftheimmune
and inﬂammatory signaling systems in both health and
disease [150, 279, 281]. Inﬂammatory processes contribute
to the onset, progression, and propagation of this common
disorder and amyloid beta peptides, key pathological lesions
of AD, are important inﬂammatory mediators, as are upreg-
ulated IL-1β and increased oxidative stress.
The established role of miR-146a in innate immu-
nity responses may also contribute to the pathogenesis16 Autoimmune Diseases
of neuroinﬂammatory CNS diseases such as MS and AD.
miRNA-146a controls TLR and cytokine signaling through a
negative feedback regulation loop involving downregulation
of TRAF6 and IRAK1 levels [150]. In neuroinﬂammation,
TLRs provide a critical link between immune stimulants and
the initiation of host defense, and TLR activation modulates
the release of inﬂammatory cytokines [282, 283]. TLRs are
expressed on cells of the CNS and can inﬂuence local CNS
immune responses. There is a marked increase in expression
of TLRs in MS brain lesions and CSF mononuclear cells as
well as in EAE brain lesions [284, 285]. The secondary pro-
gressive phase is characterized by progressive accumulation
of disability in the absence of clinical attacks and is driven by
the innate immune system [18]. However, the exact role of
speciﬁc miRNAs in these processes is unknown.
The miRNA proﬁling of microglial cells in both unstim-
ulated and stimulated conditions has not been reported. Our
preliminary study using microarray and qPCR revealed that
the expression levels of a set of miRNA were deregulated
upon LPS stimulation in N9 murine microglial cell line
(Table 3). Predicted target genes of upregulated miRNAs
detected in this preliminary study were also found to be
downregulated in a microarray study with N9 cells [286].
Validation experiments for the predicted target genes are
ongoing. Interestingly, deregulated microglial miRNAs are
somewhat diﬀerent from those detected in murine primary
macrophages or mouse Raw 264.7 macrophages upon LPS
stimulation [149, 151, 287]. Further studies for the proﬁling
of microglial miRNA expression in MS and EAE are still
warranted.
6. DiagnosticsandTherapeutic Perspectives
In patients with MS, intensive eﬀorts are directed at identify-
ing biomarkers in body ﬂuids related to underlying disease
mechanisms, disease activity and progression, and thera-
peutic response [288]. Without biomarkers, the clinical and
pathological heterogeneity of MS makes treatment diﬃcult.
Thus, identiﬁcation of biomarkers appears desirable for an
improveddiagnosisofMSaswellasformonitoringofdisease
activity and treatment response. Biomarkers are deﬁned as
parameters that are objectively measurable biological char-
acteristics, which can be used as indicators of physiologic or
pathologic processes. A valuable biomarker requires robust
and reproducible assays that work in clinically available
samples as well as archived material. As miRNAs are more
stable than mRNAs, they are good candidates for use as
disease biomarkers and their use as biomarkers has gained
growing interest in the last few years [289]. Blood serum
and plasma are important sample types for investigating
miRNAs as biomarkers. Blood biomarkers are attractive
because blood samples are easy to collect, cheaper, and
noninvasive. However, miRNA proﬁles in all body ﬂuids
such as CSF and their content including hematopoietic
cells, exosomes, microvesicles, and microparticles can be
used as diagnostic, prognostic, or monitoring marker [290,
291]. miRNA proﬁling has been established only in an AD
study [292] and has not been evaluated in the context of
MS. Besides magnetic resonance imaging parameters [166],
CSF biomarkers provide important and speciﬁc information
since changes in the CSF composition may reﬂect disease
mechanisms inherent to MS [288, 293]. miRNA proﬁling in
CSF may provide valuable information about key patholog-
ical processes of MS such as inﬂammation, demyelination,
neuroaxonalinjury,gliosis,andregeneration.Inrecentyears,
the ﬁeld of biomarker discovery has gradually shifted from
the aim of ﬁnding a single perfect surrogate marker to the
constructionofcompositemarkerswithhigherperformance.
miRNA proﬁles may be coupled with diagnostic evaluation
of miRNA targets, mRNAs, and protein output; therefore
comparison of miRNA analysis with transcriptomic and
proteomic studies represents one of the major challenges for
clinical application. Another major challenge is represented
by technological aspects of miRNA detection aimed at high
throughput, sensitivity, and accurate analysis. The level of
miRNAs in body ﬂuid samples is very low and eﬃcient and
reproducible recovery of miRNA may be problematic. Due
to their short length and high sequence similarity within
miRNA families, reliable and accurate quantiﬁcation is still
a challenge. In addition, RNA-puriﬁed plasma can also
contain inhibitors that aﬀect qPCR eﬃciency [294]. Analyses
of miRNA-associated SNPs (e.g., SNP in miRNA genes, in
miRNA binding sites in the target mRNA, or in miRNA
biogenesis pathway genes) are also potential biomarkers of
the diseases associated with miRNA dysregulation [295–
298]. While still not fully validated, proﬁling of blood cells,
exosomes, or body ﬂuid miRNAs would represent a tremen-
dous and promising advance in noninvasive diagnostics
of CNS disorders. Identiﬁcation of suitable miRNA-based
biomarker sets for MS based on parameters in peripheral
blood is only in its infancy.
While we have only just begun to gain insights into
miRNA biology, their apparent association with the onset
a n dp r o g r e s s i o no fh u m a nd i s e a s e ss u c ha sM Sh a sp r o -
duced great interest in assessing the feasibility of thera-
peutic regulation of miRNAs [299]. miRNA-based therapies
could involve administration of a speciﬁc miRNA mimic
to downregulate target genes or antisense oligonucleotide
for the blocking of certain miRNA to increase expression
of target genes. Importantly, anti-miRNA strategies may
be preferred over antisense mRNA strategies in complex
human diseases because of the potential of miRNA to aﬀect
the regulation of multiple disease-related genes. However,
because manipulation of one miRNA may have impact on
multiple mRNAs and because one mRNA may be regulated
by multiple miRNAs, it is important to guard against oﬀ-
target eﬀects. Also, miRNAs, instead of causing translational
repression or mRNA degradation, may relieve translational
repression and promote transcription [300, 301]. Another
challenge is the risk of triggering a cellular immune response
with RNA therapy. A very promising approach may be
the use of LNAs (locked nucleic acids). These molecules
comprise a class of bicyclic conformational analogues of
RNA, which exhibit high binding aﬃnity to complementary
RNA molecules and high stability in blood and tissues
in vivo [302]. Recent reports on LNA-mediated miRNA
silencing in primates support the potential of LNA-modiﬁedAutoimmune Diseases 17
Table 2: Diﬀerential miRNA expression in Multiple Sclerosis.
Sampe type Number of patients and
disease status
Speciﬁcity
of patients
and
treatment
Number
of
tested
miRNA
Results Target genes Reference
Whole bood 59 MS (18 PP, 17 SP, 24
RR) and 37 controls
Causian
No IMT 733 miR-17 and miR-20a
downregulated ND Cox
CD4+CD25+ 12 MS (RR) and 14
controls No IMT 723
miR-106b, MiR-19a,
MiR-19b and miR-25
upregulated
TGF β
signaling De Santis
CD4+, CD8+, B 8M S( R R )a n d1 0
controls (microarray) No IMT 365
miR-17-5p
upregulated in CD4+
cells
ND Lindberg
15 MS (RR)
and 10 controls (qPCR)
Peripheral blood leukocytes 43 MS (RR) Chinese ND miR 326 upreguated
in CD4+ cells Ets-1 Du
40 control miR-326 promotes
Th-17 diﬀerentiation
11 NMO
Whole bood 20 MS (RR) glatiramer
acetate (9) 866 miR-145 upregulated
in MS ND Keller
19 controls interferon-b
(10)
Whole bood 21 MS (9 remission, 4
relaps) ND 364
miR-18b and
miR-599 upregulated
in relapse
interleukine
signaling Otaegui
8c o n t r o l miR-96 upregulated
in remission
Wnt,
glutamate
Brain tissue 20 MS (16 active, 5
inactive) ND 365
miR-34a, miR-155
and miR-326
upregulated in active
lesions
CD47 Junker
9 controls
Ets-1: v-ets erythroblastosis virus E26 oncogene homolog 1; IMT: Immunmodulatory treatment; MS: Multiple sclerosis; ND: not determined; NMO:
neuromyeliis optica; PP: primary progressive; RR: Relapsing remitting, Secondary progressive.
oligonucleotides in studying miRNA functions in vivo and
in the future development of miRNA-based therapeutics
[303, 304]. LNA-modiﬁed miR-122 inhibitor has entered the
clinic and it is in phase I trials with the goal of treating
hepatitis C infection [299]. miRNAs could also be promising
potential targets or tools for new therapeutic strategies in the
treatment/preventionofautoimmunity.However,todate,no
miRNA therapies have been tested in vivo for the treatment
of autoimmune diseases.
7. Conclusion
The ﬁeld of study of miRNAs is a very rapidly evolving
new ﬁeld in molecular biology. miRNAs are important reg-
ulators of gene expression, and they function by repressing
speciﬁc target genes at the posttranscriptional level. miRNA-
mediatedregulationisessentialforimmunehomeostasisand
the prevention of autoimmune diseases. miRNA expression
is tightly regulated during hematopoiesis and lymphoid cell
diﬀerentiation and disruption of the entire miRNA network
or speciﬁc miRNAs may lead to dysregulated immune
responses. Abnormalities in miRNA expression related to
inﬂammatory cytokines, Th17 and Treg cells, as well as B
cells have been described in several autoimmune diseases.
Emerging evidence suggests that miRNA dysregulation may
contribute to the pathogenesis of MS. In the near future,
further understanding of the role of miRNAs in intracellular
signaling, the expression of proteins involved in immune
responses, modulation of cytokines and chemokines, adhe-
sion and costimulatory molecules and the interplay between
the immune system and CNS should help to deﬁne the
role of miRNAs in autoimmunity, and provide an exciting
framework for developing new biomarkers and new thera-
peutic interventions in MS. It is reasonable to assume that
future studies concerning the function of miRNAs involved
in immune responses will extend our understanding about
the complex regulatory networks in autoimmune diseases
and MS. These eﬀorts might allow the invention of novel
strategies for the treatment of MS. miRNAs are promising
reliable biomarkers of human diseases due to their stability18 Autoimmune Diseases
Table 3: Signiﬁcantly altered miRNAs upon stimulation LPS in N9 microglial cells.
MicroRNA Microarray qPCR Targets
Fold change P Fold change P
mmu-miR-105 0.35 .02 ns not determined
mmu-miR-125b-3p 2.81 ns 0.16 .047 IL-1β, IL-13, TNF-α
mmu-miR-191 3.12 ns 0.21 .032 CCL9, CRP, IL-6, TLR-3
mmu-miR-193∗ 0.26 .03 0.28 .047 CCL6, IL-10, IL-12Rγ
mmu-miR-208a 3.01 ns 0.12 .015 CD8, IL-18BP, IL-24
mmu-miR-224 3.73 ns 0.09 .033 CD53, CXCL-14, IL-11
mmu-miR-297c∗ 0.31 ns 0.12 .033 not determined
mmu-miR-324-3p 0.33 ns 0.18 .049 not determined
mmu-miR-376c 2.99 .01 ns not determined
mmu-miR-421 0.35 ns 0.03 .033 not determined
mmu-miR-431∗ 4.62 ns 0.22 .034 CD5, CD81, DICER, IRAK1, TRAP 1
mmu-miR-669g 3.48 ns 0.15 .015 not determined
mmu-miR-1190 0.28 .01 0.12 .016 not determined
mmu-miR-1894-5p 0.34 ns 0.08 .017 not determined
CCL9: chemokine (C-C) motif ligand 9; CXCL-14: chemokine (C-X-C) motif ligand 14; CRP: c reactive protein; IL-1β: interleukin 1-β; IL-6: interleukin-
6; IL-10: interleukine-10; IL-11: interleukin-11; IL-12Rγ: interleukin 12 receptor γ; IL-13: interleukin-13; IL-18BP: interleukin-18 binding protein; IL-24:
interleukin-24; IRAK1: interleukin-1 receptor associated kinase-1; TLR-3: Toll-like receptor-3; TRAP 1: TNF receptor associated protein 1; TNF-α:t u m o r
necrosis factor-α.
being less susceptible to chemical modiﬁcation and RNase
degradation. Although there is much to be learned in the
ﬁeld, the role of miRNAs in regulating a great variety of
targets and, as a consequence, multiple pathways makes
their use in diagnostics a powerful tool to be exploited
for early detection of MS, assessment for risk disease,
and monitoring both disease progression and therapeutic
responses to disease-modifying drugs.
8. Take-Home Messages
(i) miRNAshaverecentlyemergedasanewclassofmod-
ulators of gene expression at the posttranscriptional
level and are thought to play a critical role in many
biological processes.
(ii) miRNAs are involved in the development, matu-
ration, and the functions of immune cells, which
suggest that they are implicated in the development
of autoimmune diseases.
(iii) Changes of expression of some miRNAs have been
reported in autoimmune pathologies such as rheu-
matoid arthritis, systemic lupus erythematosus, and
MS.
(iv) MSserves an example ofachronic andorgan-speciﬁc
autoimmune disease in which miRNAs modulate
immune responses in the peripheral immune com-
partment and the neuroinﬂammatory process in the
brain.
(v) The diﬀerential expression of miRNAs and their role
in MS have been investigated by several studies.
(vi) miRNAs have the potential to serve as biomarkers
for the assessment of disease activity and therapeutic
response to disease-modifying drugs in MS.
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